PURPOSE: C-reactive protein (CRP) is an acute-phase protein synthesised predominantly by the hepatocytes in response to tissue damage or inflammation. It reflects the total systemic burden of inflammation of individuals and has been shown to be increased in COPD in stable condition and during exacerbations.The purpose of this study is to co-relate serum C-reactive protein levels and other clinically important predictive markers of outcome in COPD patients.
METHODS: Patients with moderate to severe airflow obstruction will be included if they had smoked 20 pack-yrs and had a post-bronchodilator FEV1/forced vital capacity (FVC) <0.7 after 400 μg of inhaled albuterol. Patients were excluded if: they had a history of asthma and/or their FEV1 increased more than 12% or 200 mL after bronchodilation; or they had bronchiectasis, tuberculosis or other confounding inflammatory diseases. The following variables, which are known to predict outcome in COPD, will be evaluated: age; dyspnoea, degree of airflow obstruction, via FEV1; Blood samples for CRP measurement will be taken after 4 h of fasting, at the same time of the day of admission .
RESULTS: 50 patients with moderate to severe COPD (GOLD Guidelines) was enrolled for the study. The mean age of the patients were (all males) 55.86±6.6. There was significant co-relation between increasing age of COPD patients and CRP values. Values of CRP increases with advancing age of the patients (−0.29; t=2.1; p<0.05), forced expiratory volume in one second(FEV1) had inverse relationship with CRP, FEV1 decreases with increase in CRP values(−0.82; t=9.9; p<0.001), similarly grade of dyspnoea increases as serum CRP increases (0.92; t=16.3; p<0.001).
CONCLUSION: CRP values had significant co-relation with clinically important predictive markers of COPD.
CLINICAL IMPLICATIONS: In patients with raised CRP levels aggressive management is required to prevent exacerbations.
DISCLOSURE: Mohammad Shameem, No Financial Disclosure Information; No Product/Research Disclosure Information